Advertisement

Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study

Published:December 28, 2011DOI:https://doi.org/10.1016/j.ajem.2011.06.003

      Abstract

      Purpose

      We hypothesized that antithrombin is more effective for disseminated intravascular coagulation (DIC) than is gabexate mesilate, which is a protease inhibitor, suggested from the previous studies. Initially, we compared the effects of antithrombin and gabexate mesilate for treating infection-related DIC.

      Methods

      Sixteen adult patients with a diagnosis of DIC with infection who were assessed with an acute DIC score 4 or higher at the admission to the intensive care unit were divided into antithrombin-treated and gabexate mesilate–treated groups. White blood cell counts, C-reactive protein, platelet counts, antithrombin, fibrin and fibrinogen degradation product, d-dimer, fibrinogen, thrombin antithrombin complex, plasmin plasminogen complex, prothrombin time, and activated partial thrombin time were measured on the day of admission and on days 1, 3, 5, and 7 thereafter. Mortality over 28 days was also compared.

      Results

      Platelet counts and antithrombin were significantly higher in the antithrombin group on day 7 and on days 5 and 7, respectively. Antithrombin increased to the normal level on day 1 in the antithrombin group but on day 7 in the gabexate mesilate group. C-reactive protein, fibrinogen degradation product, d-dimer, thrombin antithrombin complex, plasmin plasminogen complex, and prothrombin time were lower in the antithrombin group; but the differences were not significant. The 28-day mortality was 2 of 8 in the antithrombin group and 3 of 8 in the gabexate mesilate group, but they were not significantly different.

      Conclusions

      Antithrombin may be a more effective treatment for coagulation and fibrinolysis disorders than gabexate mesilate in infection-related DIC, but there was no difference in 28-day mortality.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Okamura T.
        • Niho Y.
        • Itoga T.
        • et al.
        Treatment of disseminated intravascular coagulation and its prodromal stage with gabexate mesilate (FOY): a multi-center trial.
        Acta Haematol. 1993; 90: 120-124
        • Tamaki S.
        • Wada H.
        • Hiyoyama K.
        • et al.
        Treatment of disseminated intravascular coagulation with gabexate mesilate.
        Clin Ther. 1993; 15: 1076-1084
        • Nishiyama T.
        • Matsukawa T.
        • Hanaoka K.
        Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation?.
        Crit Care Med. 2000; 28: 1419-1422
        • Inthorn D.
        • Hoffmann J.N.
        • Harti W.H.
        • et al.
        Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.
        Shock. 1998; 20: 90-96
        • Ilias W.
        • List W.
        • Decruyenaere J.
        • et al.
        Antithrombin III in patients with severe sepsis: a pharmacokinetic study.
        Intensive Care Med. 2000; 26: 704-715
        • Warren B.L.
        • Singer P.
        • Pillay S.S.
        • et al.
        High-dose antithrombin III in severe sepsis. A randomized controlled trial.
        JAMA. 2001; 286: 1869-1878
        • Aibiki M.
        • Fukuoka N.
        • Umakoshi K.
        • et al.
        Serum albumin levels anticipate antithrombin III (AT) activities before and after AT agent in critical patients with disseminated intravascular coagulation.
        Shock. 2007; 27: 139-144
        • Wada H.
        • Asakura H.
        • Okamoto K.
        • et al.
        Expert consensus for the treatment of disseminated intravascular coagulation in Japan.
        Thromb Res. 2010; 125: 6-11
        • Okabayashi K.
        • Wada H.
        • Ohta S.
        • et al.
        Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit.
        Am J Hematol. 2004; 76: 225-229
        • Takemitsu T.
        • Wada H.
        • Hatada T.
        • et al.
        Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation.
        Thromb Haemost. 2011; 105: 40-44
        • Levi M.
        • van der Poll T.
        Inflammation and coagulation.
        Crit Care Med. 2010; 38: S26-S34
        • Ohno H.
        • Kosaki G.
        • Kambayashi J.
        FOY: [Ethyl p-(6-guanidino hexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro.
        Thromb Res. 1980; 19: 579-588
        • Harada N.
        • Okajima K.
        • Kushimoto S.
        Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation.
        Crit Care Med. 1999; 27: 1958-1964
        • Murakami K.
        • Okajima K.
        • Uchiba M.
        • et al.
        Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
        Crit Care Med. 1996; 24: 1047-1053
        • Taenaka N.
        • Shimada Y.
        • Hirata T.
        • et al.
        Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis.
        Crit Care Med. 1983; 11: 735-738
        • Hsu J.T.
        • Chen H.M.
        • Chiu D.F.
        • et al.
        Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery.
        J Formos Med Assoc. 2004; 103: 678-684
        • Kaneider N.C.
        • Feistritzer C.
        • Gritti D.
        • et al.
        Expression and function of syndecan-4 in human platelets.
        Thromb Haemost. 2005; 93: 1120-1127
        • Fourrier F.
        • Jourdain M.
        • Tournoys A.
        • et al.
        Effects of a combined antithrombin III and protain C supplementation in porcine acute endotoxic shock.
        Shock. 1998; 10: 364-370
        • Gray E.
        • Thomas S.
        • Mistry Y.
        • et al.
        Inhibition of tissue factor and cytokine release.
        Haemostasis. 1996; 26: 92-95
        • Horie S.
        • Ishii H.
        • Kazama M.
        Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.
        Thromb Res. 1990; 59: 895-904
        • Uchiba M.
        • Okajima K.
        • Murakami K.
        • et al.
        Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III.
        Am J Physiol. 1996; 270: L921-L930
        • Nishiyama T.
        Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery.
        Anesth Analg. 2006; 102: 1007-1011
        • Taniguchi T.
        • Mizukoshi Y.
        • Saito S.
        • et al.
        Early effect of antithrombin III supplementation on cytokine response in septic patients with disseminated intravascular coagulation.
        Med Postgrad. 2003; 41: 126-130
        • Pulletz S.
        • Lehmann C.
        • Volk T.
        • et al.
        Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia.
        Crit Care Med. 2000; 28: 2881-2886
        • Kienast J.
        • Jures M.
        • Wiedermann C.J.
        • et al.
        Treatments effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
        J Thromb Haemost. 2006; 4: 90-97
        • Wilson R.F.
        • Farag A.
        • Mammen E.F.
        • et al.
        Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients.
        Am Surg. 1989; 55: 450-456
        • Gando S.
        • Sawamura A.
        • Hayakawa M.
        • et al.
        First day dynamic changes in antithrombin III activity after supplementation have a predictive values in critically ill patients.
        Am J Hematol. 2006; 81: 907-914
        • Nishiyama T.
        • Hanaoka K.
        Antithrombin III is useful factor in disseminated intravascular coagulation.
        Med Postgrad. 1995; 33: 242-247
        • Fourrier F.
        • Joudain M.
        • Toumoys A.
        Clinical trial results with antithrombin III in sepsis.
        Crit Care Med. 2000; 28: S38-S43
        • Blauhut B.
        • Kramar H.
        • Vinazzer H.
        • et al.
        Substitution of antithrombin III in shock and DIC: a randomized study.
        Thromb Res. 1985; 39: 81-89
        • Blauhut B.
        • Necek S.
        • Vinazzer H.
        • et al.
        Substitution therapy with an antithrombin III concentrate in shock and DIC.
        Thromb Res. 1982; 27: 271-278
        • Levi M.
        • ten Cate H.
        • van der Poll T.
        Disseminated intravascular coagulation: state of the art.
        Thromb Haemost. 1999; 82: 695-705
        • Aibiki M.
        • Fukuoka N.
        • Nishiyama T.
        • et al.
        Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study.
        Shock. 2007; 28: 141-147
        • Nishiyama T.
        • Hanaoka K.
        Can antithrombin attenuate the severity of disseminated intravascular coagulation ?.
        Med Postgrad. 2001; 39: 390-395